NAMSW — NewAmsterdam Pharma Company N.V. Warrant
NASDAQ
$16.51
+$0.00 (+0.00%)
NewAmsterdam Pharma Company N.V. Warrant (NAMSW) common stock listed on NASDAQ. It is led by Michael Harvey Davidson FACC, Facp., M.D., based in Gooimeer 2-35, Naarden, Netherlands, 1411 DC, with about 100 employees. NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Latest reported NAMSW revenue for 2025-09-30 was $348.0K. Net income was -$72.0M. Revenue was down 98.2% from 2025-06-30 to 2025-09-30.
Use this NAMSW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NAMSW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NAMSW SEC filings page. Lician reads the product cache first so this HTML stays unique to NewAmsterdam Pharma Company N.V. Warrant even when a live quote feed is slow.
About NewAmsterdam Pharma Company N.V. Warrant
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NAMSW Key Statistics
Market Cap
$0.00M
Previous Close
$16.51
Day Range
$16.51 – $16.51
EPS
-$2.56
Revenue
$45.56M
Net Income
-$241.60M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+223.4%
Profit Margin
-530.3%
Employees
100
NAMSW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $45.56M | $14.09M | $102.69M | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$241.60M | -$176.94M | -$22.63M | -$41.78M |
| EPS (Diluted) | -$2.56 | -$2.15 | -$1.19 | -$3.81 |
Total Assets
$864.62M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$771.74M
Operating Cash Flow
-$158.56M
Free Cash Flow
$0.00
NewAmsterdam Pharma Company N.V. Warrant Company Information
- CEO, President & Executive Director
- Michael Harvey Davidson FACC, Facp., M.D.
- Headquarters
- Gooimeer 2-35, Naarden, Netherlands, 1411 DC
- Website
- www.newamsterdampharma.com
- Phone
- 31 35 206 2971
- IPO / Founded
- 2022-11-23